Capricor Therapeutics Inc. (CAPR) will be presenting results from its phase 3 clinical study of lead cell therapy candidate Deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, dubbed HOPE-3, at the Muscular Dystrophy Association Clinical and Scientific Conference on March 11, 2026.
The topline results from the HOPE-3 study, reported last December, were encouraging. The study met the primary endpoint of PUL v2.0 (Performance of Upper Limb) and the key secondary cardiac endpoint of LVEF (Left Ventricular Ejection Fraction), demonstrating statistically significant improvements in both skeletal and cardiac function.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.